Status:
COMPLETED
A Trial of Erlotinib + Radiotherapy for Cutaneous Squamous Cell Carcinoma
Lead Sponsor:
University of Alabama at Birmingham
Collaborating Sponsors:
Genentech, Inc.
OSI Pharmaceuticals
Conditions:
Cancer
Eligibility:
All Genders
19+ years
Phase:
PHASE2
Brief Summary
This is a phase II study designed to study the effectiveness of combined radiotherapy and erlotinib in the postoperative setting for patients with cutaneous SCC that are at high risk for recurrence. P...
Detailed Description
This is a single-institution, open-label, non-randomized phase II trial of erlotinib administered concomitantly with radiation therapy following surgical resection of gross disease. A total of 45 pati...
Eligibility Criteria
Inclusion
- Histologically proven primary or recurrent squamous cell carcinoma arising from the lip or skin of the face, ear, scalp or neck.
- Participants must meet one of the four criteria:
- 1\. T4 cutaneous SCC as determined by physical exam, imaging studies, prior resections or biopsy. T4 disease is defined as tumor that invades deep extradermal structures such as cartilage, skeletal muscle (e.g., muscles of facial expression), parotid gland or bone.Patients with a T2 or greater squamous cell carcinoma of the lower lip who will require post operative radiation will be allowed.
- 2\. Histologically proven regional lymph node involvement (N1 disease). Fine needle aspiration or biopsy can be used to demonstrate the presence of lymphatic spread.
- 3\. Histologically proven parotid gland metastasis. Fine needle aspiration or biopsy can be used to demonstrate the presence of regional spread. Includes delayed regional metastasis; primary scalp or other skin lesion treated within 36 months that would drain into the involved parotid.
- 4\. Patients who following surgical resection of the primary are found to have histologically positive lymph nodes (N1). Includes delayed regional metastasis; primary lip or cutaneous lesion treated within 36 months that would drain into the involved nodal basin.
- Age \> 19 years
- Tumors must be considered surgically resectable.(Patients may be enrolled after surgery is completed as long as Erlotinib therapy and concurrent radiation is started within 8 weeks of surgical resection.)
- Required laboratory data obtained prior to beginning treatment: WBC \> 1,500/ml; Platelets \> 90,000; serum creatinine ≤ 2.0 mg/dl
- The patient may have had a prior non-cutaneous malignancy, but must be two years from treatment.
- Performance status of ≤ 2 (ECOG scale) and life expectancy ≥ 12 months.
- The patients must agree to use effective contraception if there is the potential for procreativity. Contraception must be conducted for at least 3 months following the study.
- Patients must sign informed consent
Exclusion
- The patient has received prior radiation therapy to the head and neck.
- The patient is pregnant or lactating
- Patients with a prior history of head and neck mucosal cancers.
- Psychological condition that renders the patient unable to understand the informed consent.
Key Trial Info
Start Date :
August 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2012
Estimated Enrollment :
15 Patients enrolled
Trial Details
Trial ID
NCT00369512
Start Date
August 1 2006
End Date
September 1 2012
Last Update
May 30 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Alabama at Birmingham Medical Center
Birmingham, Alabama, United States, 35233